Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1Pain 1Cancer Pain 1

Interventions

Radiotherapy 8Zoledronic Acid 7Fentanyl 7nabiximols 6Morphine 6Ibandronic Acid 6Ketamine 5Hydromorphone 5Analgesia 5Acetaminophen 5Tapentadol 4Oxycodone 4Acupuncture Therapy 4alvimopan 3Ropivacaine 3Prednisone 3Lidocaine 3cabozantinib 2Tetrodotoxin 2Mitoxantrone 2Gabapentin 2Duloxetine Hydrochloride 2Docetaxel 2Calcium 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2strontium chloride 1resiniferatoxin 1oxycodone-acetaminophen 1oxycodone naloxone combination 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pain × resiniferatoxin × Clear all
NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡